The influence of HER2 genotypes as molecular markers in ovarian cancer outcome
- 1 October 2005
- journal article
- clinical trial
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 335 (4) , 1173-1178
- https://doi.org/10.1016/j.bbrc.2005.08.012
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- G-308A TNF-α polymorphism is associated with an increased risk of invasive cervical cancerBiochemical and Biophysical Research Communications, 2005
- Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphismCancer Genetics and Cytogenetics, 2005
- Biological characterization of ovarian cancer: prognostic and therapeutic implicationsAnnals of Oncology, 2005
- Integrative Epidemiology: From Risk Assessment to Outcome PredictionJournal of Clinical Oncology, 2005
- Pharmacogenetics and drug development: the path to safer and more effective drugsNature Reviews Genetics, 2004
- Linkage of angiotensin I‐converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancerThe Journal of Pathology, 2004
- Glutathione S-Transferase Genotype GSTM1 as a Predictor of Elevated Angiogenic Phenotype in Patients with Early Onset Breast CancerAngiogenesis, 2004
- Cancer incidence and mortality in PortugalEuropean Journal Of Cancer, 2003
- Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S -transferase genetic polymorphisms as predictive biomarkers of disease outcomeInternational Journal of Clinical Oncology, 2003
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001